PNC Financial Services Group
AARD

PNC Financial Services Group’s Aardvark Therapeutics AARD Stock Holding History

PNC Financial Services Group’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01K Buy
349
+321
+1,146% +$1.5K ﹤0.01% 4678
2026
Q1 		$106 Buy
+28
New +$290 ﹤0.01% 5093
2025
Q4 		– Sell
-140
Closed -$1.86K – 5342
2025
Q3 		$1.86K Buy
+140
New +$1.58K ﹤0.01% 4518

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

PNC Financial Services Group's AARD Position: Q2 2026 in Review

PNC Financial Services Group increased its Aardvark Therapeutics (AARD) stake by 1,146% in Q2 2026, buying an estimated $1.5K and bringing the position to 349 shares worth $2.01K. The position accounts for ﹤0.01% of the portfolio, ranked #4678.

PNC Financial Services Group first reported a position in AARD in Q3 2025 and has held it in 3 quarters since. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • PNC Financial Services Group held 349 shares of Aardvark Therapeutics worth $2.01K as of Q2 2026.
  • PNC Financial Services Group bought 321 Aardvark Therapeutics shares in Q2 2026, an estimated $1.5K.
  • Aardvark Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4678 holding.
  • PNC Financial Services Group first reported a position in Aardvark Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.